Monthly Archives: December 2025

AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

22/12/2025 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using its lead compound masitinib, based on preclinical data

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

18/12/2025 – AB Science SA announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

15/12/2025 – AB Science today announced the publication of a new AB8939 article on the preprint platform bioRxiv

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

11/12/2025 – AB Science today announced the publication of a new article on MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study